ProShares UltraShort Dow30 (DXD) Stock Price

24.53 ▼ -0.42 (-1.68%)
Open: 24.84 Vol: 838.4K Day's range: 24.33 - 24.85 Jun 27, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
DXD Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 24.68▼ 24.64▼ 24.57▲ 25.32▼ 26.02▼
MA10 24.68▼ 24.56▲ 24.70▼ 25.92▼ 26.82▼
MA20 24.59▲ 24.75▼ 25.01▼ 25.98▼ 27.47▼
MA50 24.80▼ 25.20▼ 25.76▼ 27.18▼ 27.44▼
MA100 25.10▼ 25.82▼ 25.86▼ 27.27▼ 31.60▼
MA200 25.68▼ 25.90▼ 26.14▼ 26.92▼ 38.14▼
  5 mins 30 mins Hourly Daily Weekly
MACD 0.025▲ 0.033▲ -0.004▼ -0.093▼ -0.309▼
RSI 44.021▼ 36.023▼ 29.526▼ 31.599▼ 41.089▼
STOCH 61.202     55.590     21.587     27.013     9.982▼
WILL %R -36.667     -61.905     -74.468     -92.248▼ -98.255▼
CCI 0.201     -7.658     -55.089     -188.656▼ -105.901▼
Latest Filters Detected On DXD
▼ BREAK $DXD Price Breaks 60 Days Low Set Alert
▼ BREAK $DXD Price Breaks 30 Days Low Set Alert
▼ BREAK $DXD Price Breaks 20 Days Low Set Alert
▼ BREAK $DXD Price Breaks 10 Days Low Set Alert
ProShares UltraShort Dow30 News
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
Tuesday, June 24, 2025 03:59 AM
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.
AstraZeneca To Pay $45 Mln To Daiichi Sankyo As Datroway Gets FDA Approval For Lung Cancer | Nasdaq
Monday, June 23, 2025 11:35 PM
Datroway is a specifically engineered TROP2-directed DXd antibody drug conjugate or ADC discovered by Daiichi Sankyo, and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Monday, June 23, 2025 02:05 PM
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer ...
DXD historical stock data
date open high low close volume
27/06/25 24.84 24.85 24.33 24.53 838,400
26/06/25 25.33 25.33 24.935 24.95 582,894
25/06/25 25.32 25.58 25.31 25.42 494,600
24/06/25 25.81 25.90 25.4099 25.54 736,385
23/06/25 26.62 26.91 26.12 26.15 996,200
20/06/25 26.40 26.76 26.33 26.63 667,600
18/06/25 26.50 26.69 26.19 26.62 545,000
17/06/25 26.39 26.66 26.16 26.57 597,600
16/06/25 26.31 26.3237 25.93 26.16 857,522
13/06/25 26.20 26.7364 26.10 26.60 1,022,871
Quote Details
52wk Low:24.235
52wk High:35.79
Vol:838.4K
Avg Vol(3m):17.5M
1Y Chng:-19.34%
1M Chng:-6.91%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 0.00